|Day Low/High||5.89 / 6.18|
|52 Wk Low/High||3.61 / 11.15|
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a "perilous reversal" (up big yesterday but down big today) candidate
The Dow Jones Industrial Average clocks its seventh straight record closing Wednesday amid better-than-expected earnings from Microsoft, the best performing stock in the blue-chip index.
Here's a look at how to trade some of the most active stocks on the market right now.
Stocks are at record intraday highs by mid-afternoon Wednesday as crude oil trades above $45 and positive quarterly results for Microsoft spread earnings season cheer.
Stocks moved higher, boosted by a series of earnings reports from the likes of Microsoft, Morgan Stanley and United Continental.
Progenics (PGNX) stock is spiking today after the FDA approved its Relistor treatment for constipation.
Stocks move higher on Wednesday after a weekly reading on crude oil inventories confirms declining supplies.
Stock futures climb on Wednesday as better-than-expected earnings from Microsoft push the stock higher in premarket trading.
Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a pre-market mover with heavy volume candidate
Investors are beginning to wonder if earnings season can support the latest records.
Sales of RELISTOR tablets are expected to commence in the Third Quarter 2016
Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a weak on high relative volume candidate
Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading today, for the September 16th expiration.
Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a strong on high relative volume candidate
Doing some incremental buying in names hit by the selloff with little U.K. exposure.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Progenics Pharmaceuticals, Inc. , where a total of 6,097 contracts have traded so far, representing approximately 609,700 underlying shares.
Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2017 expiration.